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ABSTRACT - Calcium channel blockers are widely used in cardiovascular diseases, usually in long-term 
treatments, occasionally in pregnant women. The effects of verapamil were studied on uterine implantation, fetal 
reabsorption and mother’s and offspring’s plasmatic levels of calcium, phosphate and total protein. Seventy-five 
quality-controlled female Wistar rats were used. The drug-treated animals were divided in two groups: the first  
received verapamil in doses of 2.4 mg/rat/day and the second, doses of 24 mg/rat/day. The drug was 
administered by means of the drinking water for 10 weeks: 7 weeks before mating and 3 weeks during 
pregnancy; cesarean surgery was performed on the 21st. day. On the occasion of the cesarean, mother’s and 
newborn’s blood samples were taken. Verapamil, in the higher dose, caused a lowering of plasmatic calcium and 
phosphate in mothers and reduced body weight in offspring. In the young, plasmatic calcium, phosphate and 
total proteins were comparable in verapamil treated and control. However, these values were significantly lower 
in newborn of treated and control groups, as compared to their respective mothers. Results show that verapamil 
stimulated ovulation, increasing the uterine implantation but induced early fetal death and reabsorption. 
RESUMO - Os bloqueadores dos canais de cálcio são largamente utilizados em distúrbios cardiovasculares, 
usualmente em tratamentos prolongados, ocasionalmente em mulheres grávidas. Foram estudados os efeitos do 
verapamil sobre a implantação uterina, a reabsorção fetal e os níveis de cálcio, fosfato e proteínas totais 
plasmáticos de mães e filhotes. Foram utilizadas 75 ratas fêmeas Wistar, com qualidade controlada. Os animais 
tratados foram divididos em dois grupos: o primeiro recebeu verapamil na dose 2,4 mg/rato/dia de e o segundo, 
24 mg/rato/dia. A droga foi administrado na água de beber durante 10 semanas: 7 semanas antes do 
acasalamento e 3 semanas durante a gestação, sendo a operação cesariana realizada ao 21º dia. Por ocasião da 
cesariana, foram tomadas amostras de sangue das mães e filhotes. O verapamil, na dose mais elevada, causou 
diminuição dos níveis plasmáticos de cálcio e fosfato nas mães a par de diminuir o peso corpóreo dos filhotes. 
Os níveis séricos de cálcio, fosfato e proteínas foram comparáveis nos filhotes dos grupos controle e tratado. 
Contudo, foram significativamente mais baixos em todos os filhotes, em comparação com as respectivas mães. 
Os resultados mostraram que o verapamil estimulou a ovulação, aumentando o número de implantações uterinas, 
enquanto induziu morte fetal precoce e reabsorção fetal.  
Introduction 
Calcium? channel blockers are important therapeutic 
agents, used as vasodilator and antiarrhythmic drugs, 
often in long-term treatments. They prevent ionized 
calcium from entering the cell and thus influencing 
calcium-dependent processes (FLECKESTEIN et al., 
1967, 1969). Verapamil, chemically a 
phenylalkylamine, was the first drug used and is 
nowadays extensively used in the treatment of essential 
hypertension, cardiac arrhythmias and angina pectoris.
It is proposed to act on slow voltage dependent calcium 
channels of the L type (NOWICKY et al., 1985) of 
excitable cells. An extensive revision on the 
pharmacology and clinical research of calcium 
antagonists was published by VANHOUTTE et al.,
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(1988). The calcium channel blocking agents are often 
administered to women in reproductive age and during 
pregnancy. It is clinically considered to be safe and no 
teratogenic effect of verapamil has been referred. 
During our experiments, intending to observe the 
calcification of dental germ in rats born from 
verapamil-treated mothers, a very significant reduction 
in the number of offspring was observed. Such result 
leaded the present research. 
Material and Methods 
For the experiments, 57 Wistar rats in controlled 
good health conditions were used. Thirty-eight 
were virgin females, aged 90-100 days at the onset 
of the experiments and 19 were reproductive male 
rats. The animals were divided in two groups 
according to the dose of verapamil: the first one 
received the dose of 2.4 mg/rat/day (D1) named 
“lower” dose and the second received 24 
mg/rat/day (D2) named “higher” dose. Verapamil 
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was added to the drinking water. Sucrose (0.5 
g/rat/day) was mixed to the water of control and 
treated groups. A third group of untreated rats 
under the same experimental conditions was run in 
parallel as control. All the animals were weighed 
weekly. After 7 weeks of treatment with verapamil 
the estrous phase was determined, and the female 
and male rats were put together overnight for 
mating. Diagnosis of pregnancy was determined by 
presence of spermatozoa in the vaginal secretion 
(see NICHOLAS, 1949). 
Cesarean operated rats. On the 21st. day of 
pregnancy, the uterus of mothers was exposed by 
cesarean surgery under anesthesia and the number 
of fetuses, the embryonic reabsorption and uterine 
embryonic implantation (= number of embryos + 
number of embryonic reabsorption) were observed. 
The ovary was removed and the number of 
corresponding ovules released during fertilization 
was counted.  
Offspring external somatic examination. The 
newborn rats were cleaned, weighed and somatic 
external  characteristics  examined  under  lens,   3 
woth times magnification. Ears and eyes 
implantation, palate, labial cleft, anterior and 
posterior limbs and tail were examined. 
Determination of plasmatic calcium, phosphate 
and  total protein.  On  the occasion of the cesarean  
surgery, blood samples from mothers and offspring 
were collected in heparin and obtained plasma. 
Biochemical determination of calcium, inorganic 
phosphate and total protein were carried out using a 
Beckman-Du-600 Spectrophotometer. Plasmatic 
calcium was determined by compleximetric method 
of o-cresolphtalein-complexone using Merck 
Reagents. For plasmatic inorganic phosphate 
determination FISKE and SUBAROW (1925) 
method was used. Total proteins were determined 
by Biuret method, using a “Bioclin” kit reagents. 
Mathematical-statistical processing: significance 
of the difference between groups was assessed by 
non-parametric variance analysis of Kruskal Wallis. 
A multiple comparison among groups was carried 
out by using the GMC computer program version 
7.0, according to CONOVER (1980).
Results 
1 - Fetal uterine implantation. The mean number 
of fetal uterine implantation in control mothers was 
of 8.1(?2.4). In treated mothers this mean was 
significantly increased, that is: 13.0( ?2.7) with the 
lower dose (D1) and 13.3(?4.2) with the higher 
dose (D2) of verapamil. The number of uterine 
implantation corresponded to the number of ovarian 
luteinizing bodies.  
Table 1. Uterine implantation, fetal reabsorption and alive offspring (mean values) from control and verapamil treated (10 
weeks)*** group with doses of 2.4 mg/rat/day (D1) and 24.0 mg/rat/day (D2) 
Control Verapamil D1(n=18) Verapamil D2 (n=10)
Uterine implant. 
Fetal reabsorption 
Alive offspring
8.1(?2.4) 
0
8.1
13.0 (2.7%) 
5.8 (45%)* 
7.2 (55%)** 
13.3 (?4.2)
10.0 (75%)* 
3.3 (25%)**
* Percentage of fetal reabsorption; ** Percentage of alive young at cesarean surgery. *** Seven weeks before mating and 3 
weeks during pregnancy. 
2 - Fetal uterine reabsorption. No fetal uterine 
reabsorption was observed in control mothers. 
However, in the verapamil treated animals, a fetal 
uterine reabsorption of 45% occurred with doses of 
2.4 mg/rat/day (D1) and 75% with doses of 24 
mg/rat/day (D2). 
3 - Alive offspring and somatic characteristics.
In control rats, alive newborn rats corresponded to 
100% of uterine implantation. In verapamil treated  
group, the uterine implantation/alive offspring ratio 
was significantly reduced: with the lower dose, it 
corresponded to 25% and  with the higher dose, to 
55%. The weight of newborn rats from treated 
mothers was reduced in  10% (D1) and 18% (D2) 
as compared to control. No macroscopic 
malformations in control and treated groups were 
observed. Results of 1, 2 and 3 are summarized in 
Table 1. 
4 - Plasmatic calcium, phosphate and total 
protein. Plasmatic calcium and phosphate were 
significantly reduced in mothers of the groups 
treated with the higher dose (24mg/rat/day) but 
did not change when lower doses (2.4 
mg/rat/day) were used. Total protein was not 
changed by the treatment with verapamil. In 
offspring, plasmatic calcium, phosphate and total 
protein values were not changed by the verapamil 
treatment. However, a significant decrease in the 
values of calcium, phosphate and protein was 
observed as  compared to their respective 
mothers, either in treated or control. Results are 
summarized in Table 2.  
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Table 2. Rats plasmatic calcium (mg/100 ml), phosphate (mg/100 ml) and total protein (g/100 ml) from control and  verapamil 
treated groups (10 weeks)*** with doses of 2.4mg/rat/day (D1) and 24.0mg/rat/day (D2). A. – Mothers; B – Offspring.
A- Mothers Control Verapamil D1 Verapamil D2 
Calcium  
Phosphate 
Total protein 
6.13 (?0.28)
3.97 (?0.6)
7.66 (?0.8)   
6.0 (?0.27) 
3.90 (?0.12) 
7.99 (?0.52) 
5.41 (?0.68)* 
2.79 (?0.74)* 
7.07 (?0.80) 
B- Offspring Control Verapamil D1 Verapamil D2 
Calcium 
Phosphate 
Total protein 
5.27 (?0.55)** 
2.48 (?0.42)** 
3.39 (?0.33)** 
5.20 (?0.19)** 
2.42 (?0.42)**  
3.36 (? 0.33)** 
5.08 (?0.15)** 
2.47 (?0.99)** 
2.86 (?0.75)** 
Significant as compared to control. ** Significant as compared to their respective mothers. *** Seven weeks before mating 
and 3 weeks during pregnancy. 
Discussion 
There is a great medical, scientific and social 
interest and care about the teratogenicity of drugs 
when given to mothers, specially if administered early 
in the course of pregnancy. Since the dramatic episode 
of embryonic malformation – phocomelia – induced 
by thalidomide, detected in the 1960s, scientists and 
pharmaceutical industry have exhaustively studied the 
teratogenic potential of drugs, within a 
pharmacological and toxicological screening. In the 
United States, the Harris-Kefauver Amendments 
(NIES and SPIELBERG, 1996) are sound legislation 
and the total time of a drug development and final 
approval averages 8 to 9 years (DiMASI et al.,
1994). Clinical aspects of teratogenicity of drugs were 
revised by NISHMURA and TANIMURA (1976). In 
reference to verapamil, its toxicity is very well known 
and no data associates its use to congenital anomalies, 
and the drug is considered appropriated to 
administration during pregnancy. However, in the 
course of our studies on the effect verapamil on dental 
germ of offspring born from treated mothers, we 
observed a significant reduction of birth or no birth at 
all. This observation led to the present research. The 
doses of verapamil used in our experiments can be 
considered to be adequate, because during the long-
term treatment the mother rats seemed to thrive, 
increased their body weight, no disturbing behavior 
was observed and no death occurred. In the 
offspring. Verapamil caused a dose-related 
reduction of body weight, but no malformation was 
observed. To assure a regular chronic 
administration and to avoid daily stressful 
injections, the drug was added to the drinking 
water. To a better acceptance of the verapamil 
solution, sucrose was added, in both control and 
treated groups. Both doses of verapamil were 
chosen on the basis of the approximate maximal 
doses to human, that is about 7.0 mg/kg/day. To the 
rat the “small” dose (D1) corresponded to 
8.0mg/kg/day and the “high” one, was ten times 
higher - 80 mg/kg/day (D2).  Our doses are 
somewhat similar to those used by SAMNEGARD 
and SJÖDÉN (1992) who studied the influence of 
verapamil on mineralization of male and female 
bones. The dietary calcium-phosphate was adequate 
as shown by normal growth of control and treated 
rats. It is well known that the ratio of calcium to 
phosphorous in the diet exerts a marked effect upon 
growth and calcium and inorganic phosphorous 
content in the blood serum. No sign of rickets were 
observed. The daily dietary calcium and phosphate 
intake was within the range proposed by McCOY 
(1949) to normal development of the rat. Verapamil 
diminishes intestinal absorption of calcium in 
isolated and in vivo intestinal wall (WROBEL and 
MICHALSKA, 1977; SJÖDÉN et al., 1983; 
PENTO and JOHNSON, 1983) but such effect does 
not occur  in pregnant rats, in which calcium 
absorption is increased (BROMMAGE et al., 
1990). In the present research, plasmatic calcium, 
phosphate and total protein were determined in both 
mother and offspring to control how could they be 
influenced by the doses of verapamil and eventually 
explain results or health condition of the animals. 
Regarding calcium and phosphate concentrations, 
they were diminished by verapamil in mothers 
treated with the higher dose. This event could be 
related with ovulation and fetal reabsorption, but 
this could not be demonstrated, because ovulation 
was enhanced also with lower doses, which did not 
alter calcemia. As calcium and phosphate levels 
were not affected in young of any group, whether 
treated or not, a protective balance mechanism 
between mother and fetuses is indicated. An 
interesting finding was that plasmatic calcium, 
phosphate and total protein were significantly lower 
in offspring of treated and control groups (see 
Table 2). Total proteins depression was over 50%. 
The lower values can be considered “normal” to  
offspring at birth, because such a lower values were 
observed in control young, born from untreated 
mothers. The increased ovulation and higher 
embryonic uterine implantation in verapamil treated 
rats were a consistent finding. However, such 
implantation did not correspond to the fetuses at 
term, since a high degree of uterine reabsorption 
occurred. Results are suggestive in indicating that 
verapamil stimulated ovarian follicles, liberating 
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immature ova, which were fertilized but did not 
succeed in giving rise to functional ovum and fetus. 
One can speculate whether verapamil enhanced 
ovulation by itself, influencing calcium-dependent 
mechanisms or acted indirectly by stimulating 
luteinizing hormone (LH) or follicle-stimulating 
hormone (FSH), which respond to ovulation and 
corpora lutea formation. On the other hand the drug 
could act by inhibiting atresia of ovarian follicles 
not destined to produce functional ovum. Could 
verapamil be tried in experimental polycystic 
ovarian syndrome (see TOLIS et al., 1993) a 
condition in which ovulation is inhibited? As a 
matter of fact, ovulation was significantly 
stimulated even with the lower dose, which is 
similar to that therapeutically indicated in human. 
So, such effect cannot be considered a toxic but 
rather a normal one. However, no data from the 
literature refers to an enhanced ovulation by 
verapamil in women. One must consider that the 
present results, although consistent and significant, are 
preliminary, not allowing  a further discussion, but are 
suggestive to inspire further research. In a high 
percentage of the fertilized rats, verapamil induced 
partial or total uterine reabsorption. The drug is likely 
to have acted during blastogenesis, that in rats occurs 
from the 1st to the 6th day, a period when toxic action 
of drugs leads to embryo death and fetal reabsorption. 
The drug did not certainly acted during organogenesis 
(after the 6th day) because in doing so, it could lead to 
fetal malformations (teratogenesis), not observed.  
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